Novel miRNA-129–Based Therapy Achieves Over 95% Tumor Shrinkage in Preclinical NSCLC Model, Halting Drug Resistance
核心洞察
Stony Brook Cancer Center (搜索) researchers developed Gem-miR-129 (搜索), a multi-targeted therapeutic combining miRNA-129 (搜索) with gemcitabine that achieved over 95% tumor shrinkage in a murine NSCLC model.
The agent simultaneously suppresses three oncogenic driver proteins — HMGB1 (搜索), YAP1 (搜索), and PBX3 (搜索) — and enters cancer cells without requiring a delivery vehicle.
Gem-miR-129 (搜索) is designed to overcome both intrinsic and acquired resistance to chemotherapy and EGFR (搜索) tyrosine kinase inhibitors, a major cause of treatment failure in NSCLC.
A research team from the Stony Brook Cancer Center (搜索) has demonstrated that a novel multi-targeted therapeutic, Gem-miR-129 (搜索), achieved more than 95% tumor shrinkage in a murine model of non-small cell lung cancer (搜索) (NSCLC) while simultaneously preventing drug resistance. The findings, published early online in the journal Molecular Therapy, offer a proof-of-concept for a new approach to treating one of the leading causes of cancer death in the United States.
Led by Jingfang Ju, PhD, professor in the Department of Pathology in the Renaissance School of Medicine at Stony Brook University and director of the Oncogenic Drivers and Mechanisms of Carcinogenesis research arm at the Stony Brook Cancer Center (搜索), the team designed the therapy around miRNA-129 (搜索), a non-coding RNA molecule that regulates gene expression and often functions as a tumor suppressor.
A self-delivering, multi-targeted design
Gem-miR-129 (搜索) combines the natural tumor-suppressing molecule miR-129 with gemcitabine, a standard first-line chemotherapy for NSCLC. Unlike single targeted therapies, the agent can enter cancer cells independently without the need for a delivery vehicle. Once inside, it simultaneously shuts down three oncogenic driver proteins — HMGB1 (搜索), YAP1 (搜索), and PBX3 (搜索) — that promote tumor growth and contribute to therapy resistance.
"The results in the model were remarkable, with the impact of tumor shrinkage reaching more than 95 percent," said Ju. "Additionally, the survival time for the mice treated with Gem-miR-129 (搜索) increased by many weeks, which may translate to approximately 5 to 15 more years in terms of human life."
Overcoming the challenge of drug resistance
Drug resistance remains the primary reason current lung cancer therapies fail. While recent advances in targeted therapies — particularly tyrosine kinase inhibitors (TKIs) that block epidermal growth factor receptor (EGFR (搜索)) — have improved survival for a subset of NSCLC patients with EGFR mutations, approximately half of these cancers eventually acquire resistance to TKIs.
Gem-miR-129 (搜索) is specifically designed for NSCLC tumors that develop TKI resistance. The agent suppresses multiple oncogenes associated with both intrinsic and acquired resistance to chemotherapy such as gemcitabine and to EGFR (搜索) inhibitors.
Ju further detailed the agent's dual mechanism: once the gemcitabine-modified component is released from Gem-miR-129 (搜索), low-dose gemcitabine inhibits tumor-infiltrated T regulatory cells (Ti-Tregs), which normally block cytotoxic T cells (CD4 and CD8) from eliminating tumor cells. By reducing Ti-Tregs, the agent removes the inhibitory effect on the immune response, enabling CD4 and CD8 T cells to reduce tumor burden.
Safety profile and next steps
No noticeable toxic side effects were observed in the preclinical model. "Resistance is the primary reason why current lung cancer therapies stop working for cancer patients, and for that reason, this approach is highly promising," Ju stressed. "We believe this new approach provides a proof-of-concept for future studies that could lead to clinical trials in NSCLC patients."
The team's next step will be to pursue Investigational New Drug (IND) studies for Gem-miR-129 (搜索), a process designed to establish the drug's safety profile with the goal of gaining regulatory approval for human clinical trials.
The research was supported in part by a Veterans Affairs Merit Award and by a Stony Brook Cancer Center (搜索) Pilot Fund.